Competitor Landscape: CKD-MBD

Competitor Landscape: CKD-MBD

Summary

"Competitor Landscape: CKD-MBD", briefings contain evaluations of ongoing development activities within the CKD-MBD disease markets, together with analysis of current & potential future product positioning.

Key Highlights from the report -

• OPKO appears to be currently focusing resources on the commercialization and continued development of the SHPT therapy Rayaldee (calcifediol ER), which may result in further delays to Alpharen’s development


• While the main challenge for Velphoro remains the market dominance of branded & generic sevelamer, the real-world evidence from trials like VERIFIE are expected to strengthen the value proposition for VERIFIE and encourage its use over older phosphate binders


• Positive findings from a trial comparing the efficacy of Velphoro and sevelamer carbonate for lowering and maintaining serum phosphate levels in adult Chinese DD-CKD subjects may support a future approval in China, and generate new revenue streams for Vifor

The report comprises four key sections.

Executive Summary: Contains analysis of key market events that have occurred during the previous quarter and which have impacted the CKD-MBD landscape.

CKD-MBD Pipeline Landscape: Section contains the following analysis -

• An overview of pipeline candidates, containing snapshots of current development status


• ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher


• Expected drug-specific events & milestones until YE 2019

CKD-MBD Approved Product Landscape: Section contains the following analysis -

• Timeline forecasts for each approved product’s lifecycle management initiatives


• Expected drug-specific events & milestones until YE 2020


• ‘Direction of Travel’ positioning analysis for currently approved therapies

Appendix: Data slides containing the following information -

• Current Early Stage CKD-MBD and Pipeline & candidate ‘Watch List’


• Timeline Assumptions, including standard assumptions + drug-specific assumptions

Scope

• The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)


• Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix


• Forecasts are presented in pipeline forecast figures & detailed tables


• ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to Buy

• Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher


• Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market


• Reviews ongoing lifecycle management strategies for existing players in the market


• A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.